Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Eclipse Surgical Technologies

This article was originally published in The Gray Sheet

Executive Summary

Eclipse Surgical Technologies: Sunnyvale, California-based firm receives investigational device exemption approval from FDA to commence clinical trials of its laser transmyocardial revascularization (TMR) procedure as an adjunct to minimally invasive direct coronary artery bypass surgery (MIDCAB) for the treatment of heart disease. Commercially available in Europe since December, the TMR laser also is undergoing a Phase II study comparing the treatment alone to conventional drug therapy in patients with severe angina. Another Phase II trial underway is comparing TMR and coronary artery bypass graft (CABG) surgery with CABG alone...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT007453

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel